Www.sanofi.com.au

Feb 05, 2018 · Sanofi’s Australia and New Zealand Country Medical Chair, Dr Paul King, said there continues to be a high unmet medical need for patients with moderate-to-severe atopic dermatitis. “Registration of Dupixent is an important step toward bringing effective, long-term treatment options to these patients in Australia.” ................
................